Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 8, 2026

Tesla’s vote wasn’t about pay. It was about who really runs the company

View original at finance.yahoo.com
Tesla’s vote wasn’t about pay. It was about who really runs the company At Tesla’s 2025 Annual Meeting, something significant and important happened…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Derivative lawsuits are too often exploited as vehicles for opportunistic litigation, enriching plaintiff lawyers at the expense of shareholders

    80% confidence
  • Tesla shareholders voted according to what they believed was in their financial interest and would create long-term value, exercising independent judgment rather than following proxy advisory firms

    80% confidence
  • The days of blind deference to advisory firms that fail to appreciate the complexities of modern-day businesses are coming to an end

    80% confidence
  • Proxy advisory tools are increasingly misaligned with the realities of the modern economy and cannot meaningfully assess companies operating at the frontier of technological transformation

    80% confidence
  • Even excluding shares held by Elon Musk, the proposals passed by over 70%, well over the required majority threshold

    80% confidence
  • The 2025 CEO Performance Award has no salary, no cash bonus, and no payout unless extraordinary milestones are reached

    80% confidence
  • Tesla's compensation plan is excessive and unconventional

    80% confidence
  • Tesla operates across artificial intelligence, robotics, autonomous solutions, energy systems, semiconductor development, and advanced manufacturing

    80% confidence
  • Shareholders have affirmed the substance of the 2018 CEO Performance Award on three separate occasions, each with support exceeding 75% of votes cast

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Tesla’s vote wasn’t about pay. It was about who really runs the company — Source | Via News | ViaNews Market